UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

The lancet oncology, 2017, Vol.18 (1), p.75-87

2017

Volltextzugriff (PDF)

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity

Journal of clinical oncology, 2013-12, Vol.31 (35), p.4453-4461

2013

Volltextzugriff (PDF)

Evaluation of Drug–Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor

Clinical and translational science, 2019-01, Vol.12 (1), p.58-65

2019

Volltextzugriff (PDF)

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors

Clinical cancer research, 2017-08, Vol.23 (15), p.4095-4106

2017

Volltextzugriff (PDF)

Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial

Gynecologic oncology, 2023-08, Vol.175, p.1-7

2023

Volltextzugriff (PDF)

Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”

PharmacoEconomics, 2019-08, Vol.37 (8), p.1065-1067

2019

Volltextzugriff (PDF)

Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors

Investigational new drugs, 2020-06, Vol.38 (3), p.765-775

2020

Volltextzugriff (PDF)

Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody

European journal of cancer (1990), 2014-07, Vol.50 (11), p.1891-1899

2014

Volltextzugriff (PDF)

Abstract B102: A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation

Cancer research (Chicago, Ill.), 2015-07, Vol.75 (13_Supplement), p.B102-B102

2015

Volltextzugriff (PDF)

ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS5619-TPS5619

2014

Volltextzugriff (PDF)

Evaluation of Drug–Drug Interactions of Rucaparib and CYP 1A2, CYP 2C9, CYP 2C19, CYP 3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor

Clinical and translational science, 2019-01, Vol.12 (1), p.58-65

2019

Volltextzugriff (PDF)

The hENT1 Immunohistochemistry Diagnostic Test is Predictive of Gemcitabine Outcome in Pancreatic Ductal Adenocarcinoma: 195

The American journal of gastroenterology, 2012-10, Vol.107, p.S84-S85

2012

Volltextzugriff (PDF)

The Effect of Personal Cultural Orientations on Consumer Decision-Making Styles Through Consumer Involvement

Isaacson, Jeff Ian

2017

Volltextzugriff (PDF)

Abstract 4670: A novel companion diagnostic predicts response to the PARP inhibitor rucaparib in ovarian cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4670-4670

2015

Volltextzugriff (PDF)

P-0099 Two-Thirds of Pancreatic Ductal Adenocarcinomas have low Expression of Hent1 as Determined by the Sp120 Rabbit Monoclonal Antibody Immunohistochemistry Test

Annals of oncology, 2012-06, Vol.23, p.iv59-iv60

2012

Volltextzugriff (PDF)

Award-winning expertise for Pungue River bridge

Civil Engineering : Magazine of the South African Institution of Civil Engineering, 2005-03, Vol.13 (3), p.20-21

Isaacson, Jeff

2005

Volltextzugriff (PDF)

Occurrence and Mass Distribution of Close-in Super-Earths, Neptunes, and Jupiters

Science (American Association for the Advancement of Science), 2010-10, Vol.330 (6004), p.653-655

2010

Volltextzugriff (PDF)

The California Planet Survey. I. Four New Giant Exoplanets

The Astrophysical journal, 2010-10, Vol.721 (2), p.1467-1481

2010

Volltextzugriff (PDF)

The Breakthrough Listen Search for Intelligent Life: Public Data, Formats, Reduction, and Archiving

Publications of the Astronomical Society of the Pacific, 2019-12, Vol.131 (1006), p.124505

2019

Volltextzugriff (PDF)

The Curious Case of KOI 4: Confirming Kepler's First Exoplanet Detection

The Astronomical journal, 2019-05, Vol.157 (5), p.192

2019

Volltextzugriff (PDF)

Teaching neurologists through microlearning: the first 4 years of the eLearning experience with NeuroBytes (P13-2.001)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Demonstrating the Clinical Impact of Continuous Glucose Monitoring Within an Integrated Healthcare Delivery System

Journal of diabetes science and technology, 2022-03, Vol.16 (2), p.383-389

2022

Volltextzugriff (PDF)

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort

Annals of clinical and translational neurology, 2018-12, Vol.5 (12), p.1460-1477

2018

Volltextzugriff (PDF)

A Randomized Feasibility Trial of a Novel, Integrative, and Intensive Virtual Rehabilitation Program for Service Members Post-Acquired Brain Injury

Military medicine, 2020-02, Vol.185 (1-2), p.e203-e211

2020

Volltextzugriff (PDF)

Status of neurology medical school education: results of 2005 and 2012 clerkship director survey

Neurology, 2014-11, Vol.83 (19), p.1761-1766

2014

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(49)
Dissertationen
(1)

Sprache

Englisch
(50)

Erscheinungsjahr

n.n

Thema

Science & Technology
(29)
Physical Sciences
(15)
Astronomy & Astrophysics
(13)
Life Sciences & Biomedicine
(13)
Astronomy
(12)
Planets
(11)
Earth, Ocean, Space
(10)
Exact Sciences And Technology
(10)
Planetary Systems
(10)
Humans
(9)
Stars
(9)
Radial Velocity
(8)
Astrophysics, Cosmology And Astronomy
(7)
Oncology
(7)
Orbits
(7)
Stars: Individual
(7)
Aged
(6)
Extrasolar Planets
(5)
Female
(5)
Mass
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity

Evaluation of Drug–Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors

Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial

Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”

Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors

Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody

Abstract B102: A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation

ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response

Evaluation of Drug–Drug Interactions of Rucaparib and CYP 1A2, CYP 2C9, CYP 2C19, CYP 3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor

The hENT1 Immunohistochemistry Diagnostic Test is Predictive of Gemcitabine Outcome in Pancreatic Ductal Adenocarcinoma: 195

The Effect of Personal Cultural Orientations on Consumer Decision-Making Styles Through Consumer Involvement

Abstract 4670: A novel companion diagnostic predicts response to the PARP inhibitor rucaparib in ovarian cancer

P-0099 Two-Thirds of Pancreatic Ductal Adenocarcinomas have low Expression of Hent1 as Determined by the Sp120 Rabbit Monoclonal Antibody Immunohistochemistry Test

Award-winning expertise for Pungue River bridge

Occurrence and Mass Distribution of Close-in Super-Earths, Neptunes, and Jupiters

The California Planet Survey. I. Four New Giant Exoplanets

The Breakthrough Listen Search for Intelligent Life: Public Data, Formats, Reduction, and Archiving

The Curious Case of KOI 4: Confirming Kepler's First Exoplanet Detection

Teaching neurologists through microlearning: the first 4 years of the eLearning experience with NeuroBytes (P13-2.001)

Demonstrating the Clinical Impact of Continuous Glucose Monitoring Within an Integrated Healthcare Delivery System

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort

A Randomized Feasibility Trial of a Novel, Integrative, and Intensive Virtual Rehabilitation Program for Service Members Post-Acquired Brain Injury

Status of neurology medical school education: results of 2005 and 2012 clerkship director survey

Suchergebnisse filtern